REG - Kanabo Group PLC - Partnership to launch a Walk-In Pain Clinic

KanaboAnnouncement

15/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240115:nRSO6124Za&default-theme=true

RNS Number : 6124Z  Kanabo Group PLC  15 January 2024

 

15 January 2024

Kanabo Group Plc

("Kanabo", the "Group" or the "Company")

 

Partnership with City Dock Pharmacy to launch a Walk-In Pain Clinic

 

UK's first walk-in clinic for pain management delivering specialised medicine,
including medicinal cannabis

 

Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health
services and specialist medicines, including medicinal cannabis, is pleased to
announce it has signed a partnership with City Dock Pharmacy in London, to
launch a walk-in pain clinic offering specialised medicines, including
medicinal cannabis, which is the first of its kind.

 

The pain clinic, which will be based at City Dock Pharmacy in Wapping, London,
will offer both appointment-based and walk-in services. The clinic will
leverage Kanabo's Treat It online platform, and pharmacists will be on hand to
guide patients through the medicinal cannabis treatment options. Furthermore,
the clinic supports the delivery of personalised treatment plans for the
growing number of chronic pain sufferers in the UK, who often face
difficulties accessing medical treatments due to long waiting times,
bureaucracy and affordability.

 

The partnership with City Dock Pharmacy will combine Kanabo's expertise in
medicinal cannabis with traditional treatments for pain management and will
cater for patients who are eligible for alternative therapies, as traditional
treatments have not delivered improvements. The partnership with City Dock
Pharmacy should result in an increase of patients who receive treatment
through Kanabo's Treat It platform.

 

The launch of the walk-in pain clinic with City Dock Pharmacy represents
progress against the Group's strategy, as announced on 29 September 2023, to
extend its reach into physical pharmacies across the UK offering Kanabo's
services to patients. The Company will seek to replicate this model across
more pharmacies, leveraging the extensive pharmacy network partnership in
Kanabo's digital health division.

 

Avihu Tamir, Chief Executive Officer of Kanabo, commented:

 

"This collaboration is a testament to our dedication to innovating in pain
management. The combination of City Dock Pharmacy's trusted presence and our
expertise in medicinal cannabis paves the way for a new, holistic approach to
treating pain and the opportunity to extend this to additional indications."

 

 

Enquiries:

                                                                  via Vigo Consulting

 Kanabo Group plc                                                 +44 (0)20 7390 0230

 Avihu Tamir, Chief Executive Officer

 Assaf Vardimon, Chief Financial Officer

 Ian Mattioli, Non-Executive Chair of the Board

 Peterhouse Capital Limited (Financial Adviser and Broker)        +44 (0)20 7469 0930

 Eran Zucker / Lucy Williams / Charles Goodfellow

 Vigo Consulting (Financial Public Relations/Investor Relations)   +44 (0)20 7390 0230

 Jeremy Garcia / Fiona Hetherington / Verity Snow

 kanabo@vigoconsulting.com (mailto:kanabo@vigoconsulting.com)

 

About Kanabo Group plc

Kanabo Group plc (LSE:KNB) is a digital health company committed to
transforming patient care through its innovative technology platform and
specialised treatment offerings. Since its inception in 2017, Kanabo has been
focused on researching, developing, and commercialising regulated medicinal
cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides
patients with video consultations, online prescriptions, and primary care
services. Leveraging its telehealth capabilities, in February 2023, Kanabo
launched Treat It - an online clinic focused on chronic pain management
providing patients with secondary care.

 

With its two complementary business divisions, Kanabo has established itself
as an end-to-end digital health provider, offering telehealth consultations,
prescriptions, alongside the delivery of tailored treatments.

 

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation
consultancy supporting cannabis businesses in developing new farms through
infrastructural, research, and product guidance. These farms deliver
high-quality raw materials for Kanabo's formulas and product line.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest
quality medical treatments and more accessible healthcare experiences.

Visit (http://www.kanabogroup.com/) www.kanabogroup.com
(http://www.kanabogroup.com/) for more information.

 

 

About City Dock Pharmacy

City Dock Pharmacy, based in Wapping, London, is at the cutting edge of
innovative healthcare. This patient-focused team bridges the gap between
traditional and modern medical treatments, serving both NHS and private
patients with advanced healthcare technologies.

 

The pharmacy has an in-house beauty clinic offering various services such as
facials, anti-wrinkle injections, Platelet Rich Plasma (PRP) therapy and
dermal fillers.

 

Complementing these offerings is a Pain Management Clinic, which provides
expert advice on medical cannabis and various herbal medications, showcasing
its comprehensive approach to health and wellness.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPFLFFFLEFA